OnDosis: Funding, Investors & Team (Sep 2026)

OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. They are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with a significant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes. The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal. OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.

OnDosis has raised $11.1M across 1 round on record. The most recent is an undisclosed round of $11.1M announced in May 2021.

OnDosis' most recent funding round on record is an undisclosed round of $11.1M, announced in May 2021.

Martin Olovsson is listed as CEO at OnDosis.

OnDosis is based in Mölndal, Vastra Gotaland, Sweden.

OnDosis is in the 11-50 employee band.

OnDosis' latest round of $11.1M is above the $4.7M median round size for Health Care companies on FundedIQ across 3,653 tracked companies over the last two years.